Nanobiotix (NBTX): which funds own it
A 13F shows the portfolio at quarter-end and is filed up to 45 days later: these are not real-time positions and they may have changed.
Sections with a free account
No concentrated manager holds it.
Who owns Nanobiotix?
Nanobiotix trades in the U.S. through ADRs, certificates that represent shares of a non-U.S. company. Form 13F counts ADRs while the company reports ordinary shares, so we do not compute percentages. Holders reporting more than 5% of the ordinary shares to the SEC (Schedules 13D/13G): Invus Public Equities, 9.4% (13G/A filed Aug 13, 2026) and Qatar Investment Authority, 7.0% (13G/A filed Jul 29, 2026). As of Jun 30, 2026, the largest ADR holders reported on Form 13F were Johnson & Johnson (5.6 million ADRs), Morgan Stanley (49,789 ADRs) and Jane Street Group (32,180 ADRs).
Which institutions hold the most Nanobiotix shares?
Per Form 13F filings as of Jun 30, 2026, in ADRs:
- 1. Johnson & Johnson: 5.6 million ADRs
- 2. Morgan Stanley: 49,789 ADRs
- 3. Jane Street Group: 32,180 ADRs
- 4. HRT Financial: 27,332 ADRs
- 5. XTX Topco: 15,855 ADRs
- 6. Optiver Holding B.V: 13,631 ADRs
- 7. Wace, Llp Marshall: 10,044 ADRs
- 8. Citadel Advisors: 6,042 ADRs
- 9. BNP Paribas Financial Markets: 4,044 ADRs
- 10. UBS Group: 2,577 ADRs
Sources:13G/A by Invus Public Equities (Aug 13, 2026) ↗13G/A by Qatar Investment Authority (Jul 29, 2026) ↗All of the company's proxy statements on EDGAR ↗
We hold 13D and 13G filings made since Dec 23, 2024: a holder above 5% that has not filed since then does not appear here.
Quarter flow (concentrated managers)
Concentrated managers holding it
None in the latest quarter.
Other relevant holders
Filers with $100M or more in the stock that do not count as concentrated managers because of their type: they are left out of the counts, the consensus and the accumulation.
- Johnson & JohnsonOperating company$175M23.0%
Largest holders of NBTX (all 13F filers)
- Johnson & Johnson5.6 MOperating company0
- Morgan Stanley50 KBank or trading desk+14 K
- Jane Street Group32 KBank or trading desk+32 K
- HRT Financial27 KBank or trading desk+27 K
- XTX Topco16 KType not verified+16 K
- Optiver Holding B.V14 KBank or trading desk+130
- Wace, Llp Marshall10 KInvestment firm+805
- Citadel Advisors6,042Quant or multi-manager+6,042
- BNP Paribas Financial Markets4,044Bank or trading desk+485
- UBS Group2,577Bank or trading desk−2,980
- Shares
- 5.6 M
- Change
- 0
See more
- Type
- Operating company
- Value
- $212M
- Shares
- 50 K
- Change
- +14 K
See more
- Type
- Bank or trading desk
- Value
- $1.9M
- Shares
- 32 K
- Change
- +32 K
See more
- Type
- Bank or trading desk
- Value
- $1.2M
- Shares
- 27 K
- Change
- +27 K
See more
- Type
- Bank or trading desk
- Value
- $1.0M
- Shares
- 16 K
- Change
- +16 K
See more
- Type
- Type not verified
- Value
- $598K
- Shares
- 14 K
- Change
- +130
See more
- Type
- Bank or trading desk
- Value
- $514K
- Shares
- 10 K
- Change
- +805
See more
- Type
- Investment firm
- Value
- $379K
- Shares
- 6,042
- Change
- +6,042
See more
- Type
- Quant or multi-manager
- Value
- $228K
- Shares
- 4,044
- Change
- +485
See more
- Type
- Bank or trading desk
- Value
- $152K
- Shares
- 2,577
- Change
- −2,980
See more
- Type
- Bank or trading desk
- Value
- $97.2K
The 10 13F filers with the most shares as of Jun 30, 2026, whatever their type (index firms usually come first). “Change”: shares added or cut versus the previous quarter, split-adjusted; “no data” = there is no comparable portfolio for the previous quarter (no filing, or a filing with its holdings under confidential treatment). “% of the company” only where shares outstanding are up to date. Entities of the same group file separately and some 13F filings include other managers: there may be double counting. With a free account: the top 25, the largest buyers and the largest sellers.
Insiders (Form 4)
Open-market purchases, excluding 10b5-1 plans. Officers and directors only; joint filers of the same purchase count as one. 10% owners with no role are shown separately. 0 = nobody bought; “no data” = we do not have its Form 4 filings.
Each of the company's Form 4 filings, on EDGAR ↗Latest trades, with date and filing →
Above 5% (13D/13G)
Disclosed stakes, with their amendments. A filing is not always a purchase: there are also reductions and changes of filing entity.
This list may be incomplete: we hold 13D and 13G filings made since Dec 23, 2024. A holder above 5% that has not filed anything since then is not shown here.
Above 5% over time (13D/13G)
Each holder with its filings in order. History since December 2024.
This company filed no 8-K forms in the last year. Foreign companies listed in the US (ADRs) report material events on forms 6-K and 20-F, and ETFs and funds do not file 8-Ks. If it is a foreign company listed in the US through ADRs (American Depositary Receipts), what trades are bank-issued certificates that represent shares from its home market. See its filings on EDGAR ↗
Other Health Care stocks in managers' portfolios
Same sector and a similar number of concentrated managers holding them. It is a list to keep exploring, not a recommendation.
- Agios PharmaceuticalsAGIO · 4 managers
- DavitaDVA · 4 managers
- KardiganKARD · 4 managers
- MapLight TherapeuticsMPLT · 4 managers
- Anteris Technologies GlobalAVR · 5 managers
- Compass TherapeuticsCMPX · 5 managers